Systematic Review of topotecan (Hycamtin) in relapsed small cell lung cancer

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Riemsma, Rob ^a   Simons, Jean P ^a,b   Bashir, Zahid ^c   Gooch, Caroline L ^c   Kleijnen, Jos ^a,d  

^a KLEIJNEN SYSTEMATIC REVIEWS LTD   (United Kingdom)

^b Microvida Laboratory for Medical Microbiology and Immunology   (Netherlands)

^c GLAXOSMITHKLINE   (United Kingdom)

^d MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; TOPOTECAN; VINCRISTINE; DNA TOPOISOMERASE INHIBITOR;

ANEMIA; ARTICLE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; COCHRANE LIBRARY; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG INDICATION; EMBASE; HUMAN; INTERMETHOD COMPARISON; LIVER METASTASIS; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LUNG SURGERY; MEDICAL DECISION MAKING; MEDICAL RESEARCH; MEDLINE; METHODOLOGY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PATIENT ATTITUDE; PATIENT CARE; QUALITY OF LIFE; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT OUTCOME; LUNG TUMOR; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TUMOR RECURRENCE;

HUMANS; LUNG NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SMALL CELL LUNG CARCINOMA; TOPOISOMERASE INHIBITORS; TOPOTECAN;

EID: 77955532240     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-436     Document Type: Article

References (21)

1. Office for National Statistics. Cancer statistics registrations Registrations of cancer diagnosed in 2005, England. 2008, Newport, HMSO; Series MB1 no. 36, Office for National Statistics. Cancer statistics registrations.
2. Welsh Cancer Intelligence & Surveillance Unit Cancer Incidence in Wales 2002-2006. WCISU; SA8/01. 2008, Cited 4-6-2009, Welsh Cancer Intelligence & Surveillance Unit., http://www.wales.nhs.uk/sites3/Documents/242/incpub2006%5F31Jan08.pdf
3. Hyde L, Yee J, Wilson R, Patno ME. Cell type and the natural history of lung cancer. JAMA 1965, 193:52-54.
4. Lassen U, Osterlind K, Hansen M, Dombernowsky P, Bergman B, Hansen HH. Longterm survival in small-cell lung cancer: posttreatment characteristics in patients surviving 5 to 18+ years - an analysis of 1,714 consecutive patients. J Clin Oncol 1995, 13(5):1215-1220.
5. Rawson NS, Peto J. An overview of prognostic factors in small cell lung cancer. A report from the Subcommittee for the Management of Lung Cancer of the United Kingdom Coordinating Committee on Cancer Research. Br J Cancer 1990, 61:597-604. 1971381, 2158808.
6. National Collaborating Centre for Acute Care Diagnosis and treatment of lung cancer. National Collaborating Centre for Acute Care, February 2005, London. 2009, http://www.nice.org.uk/nicemedia/pdf/cg024fullguideline.pdf. Cited 2-6-2009, National Collaborating Centre for Acute Care., http://www.rcseng.ac.uk
7. EMEA Report - Scientific Discussion; Procedure No. EMEA/H/C/123/II/34; EMEA, London, 6 January 2006. 2006, Cited 2-6-2009., http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion_-_Variation/human/000123/WC500051543.pdf
8. Seidenfeld J, Samson DJ, Bonnell CJ, Ziegler KM, Aronson N. Management of Small Cell Lung Cancer. Evidence Report/Technology Assessment No. 143. (Prepared by Blue Cross and Blue Shield Association Technology Evaluation Center Evidence-based Practice Center under Contract No. 290-02-0026.) AHRQ Publication No. 06-E016. 2006, Rockville, MD, Agency for Healthcare Research and Quality.
9. O'Brien MER, Ciuleanu TE, Tsekov H, Shparyk Y, Cucevia B, Juhasz G, Thatcher N, Ross GA, Dane GC, Crofts T. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 2006, 24:5441-5447. 10.1200/JCO.2006.06.5821, 17135646.
10. Spiro SG, Souhami RL, Geddes DM, Ash CM, Quinn H, Harper PG, Tobias JS, Partridge M, Eraut D. Duration of chemotherapy in small cell lung cancer: a Cancer Research Campaign trial. Br J Cancer 1989, 59:578-583. 2247136, 2540788.
11. Puhan MA, Bachmann LM, Kleijnen J, Ter Riet G, Kessels AG. Inhaled drugs to reduce exacerbations in patients with chronic obstructive pulmonary disease: a network metaanalysis. BMC Medicine 2009, 14:2.
12. Higgins JPT, Green S, . editors Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 [updated September 2008] 2008, The Cochrane Collaboration, editors.
13. Bucher HC, Guyatt GH, Griffiths LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 2009, 50:683-691.
14. Von Pawel J, Schiller JH, Shepherd FA, Fields SZ, Kleisbauer JP, Chrysson NG, Stewart DJ, Clark PI, Palmer MC, Depierre A, Carmichael J, Krebs JB, Ross G, Lane SR, Gralla R. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999, 17:658-667.
15. Von Pawel J, Gatzemeier U, Pujol JL, Moreau L, Bildat S, Ranson M, Richardson G, Steppert C, Riviere A, Camlett I, Lane S, Ross G. Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer. J Clin Oncol 2001, 19:1743-1749.
16. Eckardt JR, Von Pawel J, Pujol JL, Papai Z, Quoix E, Ardizzoni A, Poulin R, Preston AJ, Dane G, Ross G. Phase II study of oral compared with intravenous topotecan as second line therapy in small-cell lung cancer. J Clin Oncol 2007, 25:2086-2092. 10.1200/JCO.2006.08.3998, 17513814.
17. O'Bryan MR, Crowley JJ, Kim PN, Epstein RB, Neilan B, Coltman CA, Stuckey WJ, Pazdur R. Comparison of etoposide and cisplatin with bis-chloroethylnitrosourea, thiotepa, vincristine, and cyclophosphamide for salvage treatment in small cell lung cancer. A Southwest Oncology Group Study. Cancer 1990, 65:856-860. 10.1002/1097-0142(19900215)65:4<856::AID-CNCR2820650404>3.0.CO;2-6, 2153435.
18. Gervais R, Le Guen Y, Le Caer H, Chouaid C, . et le Groupe Francais de Pneumo Cancerologie (GFPC) Randomised phase II study evaluating oral combination chemotherapy (CCNU, cyclophosphamide, etoposide) and intravenous chemotherapy as second-line treatment for relapsed small cell bronchial carcinoma (Trial GFPC0501). Rev Mal Respir 2007, 24:653-658. et le Groupe Francais de Pneumo Cancerologie (GFPC).
19. Inoue A, Sugawara S, Yamazaki K, Maemondo M, Suzuki T, Gomi K, Takanashi S, Inoue C, Inage M, Yokouchi H, Watanabe H, Tsukamoto T, Saijo Y, Ishimoto O, Hommura F, Nukiwa T. Randomized Phase II Trial Comparing Amrubicin With Topotecan in Patients With Previously Treated Small-Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 0402. J Clin Oncol 2008, 26:5401-5406. 10.1200/JCO.2008.18.1974, 18854562.
20. Liu G, Franssen E, Fitch MI, Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997, 15:110-115.
21. Cheng S, Evancs WK, Stys-Norman D, Shepherd FA, . the Lung Cancer Disease Site Group of Cancer Ontario's Program in Evidence-based Care Chemotherapy for relapsed small cell lung cancer: a systematic review and practice guideline. J Thorac Oncol 2007, 2:348-354. 10.1097/01.JTO.0000263720.15062.51, 17409809, the Lung Cancer Disease Site Group of Cancer Ontario's Program in Evidence-based Care.